Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veronika Sexl

Showing results (1-10 of 190) with videos related to

Pageof 19
Sort By:
Blood|October 6, 2022
STAT1 and MHCII: guardians of stressed HSCsSebastian Kollmann, Veronika Sexl
Frontiers in Immunology|February 3, 2017
STATs in NK-Cells: The Good, the Bad, and the UglyDagmar Gotthardt, Veronika Sexl
Oncotarget|October 29, 2013
CDK6 and p16INK4A in lymphoid malignanciesKaroline Kollmann, Veronika Sexl
JAK-STAT|September 24, 2013
The tumor suppressor function of STAT1 in breast cancerAntonis E Koromilas, Veronika Sexl
Molecular & Cellular Oncology|September 29, 2018
Cdk6: At the interface of Rb and p53Sofie Nebenfuehr, Florian Bellutti, Veronika Sexl
Blood|August 9, 2013
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemiaWolfgang Warsch, Christoph Walz, Veronika Sexl
Oncotarget|July 27, 2011
c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguardKaroline Kollmann, Gerwin Heller, Veronika Sexl
Leukemia & Lymphoma|April 10, 2008
Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies?Eva Zebedin, Michael Freissmuth, Veronika Sexl
Pharmaceuticals (Basel, Switzerland)|December 1, 2020
CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer TreatmentLisa Scheiblecker, Karoline Kollmann, Veronika Sexl
Cell Death and Differentiation|May 13, 2017
It is a differentiation game: STAT5 in a new roleBarbara Maurer, Matthias Farlik, Veronika Sexl
Pageof 19

Showing results (1-10 of 190) with videos related to

Sort By:
Pageof 19
Blood|October 6, 2022
STAT1 and MHCII: guardians of stressed HSCsSebastian Kollmann, Veronika Sexl
Frontiers in Immunology|February 3, 2017
STATs in NK-Cells: The Good, the Bad, and the UglyDagmar Gotthardt, Veronika Sexl
Oncotarget|October 29, 2013
CDK6 and p16INK4A in lymphoid malignanciesKaroline Kollmann, Veronika Sexl
JAK-STAT|September 24, 2013
The tumor suppressor function of STAT1 in breast cancerAntonis E Koromilas, Veronika Sexl
Molecular & Cellular Oncology|September 29, 2018
Cdk6: At the interface of Rb and p53Sofie Nebenfuehr, Florian Bellutti, Veronika Sexl
Blood|August 9, 2013
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemiaWolfgang Warsch, Christoph Walz, Veronika Sexl
Oncotarget|July 27, 2011
c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguardKaroline Kollmann, Gerwin Heller, Veronika Sexl
Leukemia & Lymphoma|April 10, 2008
Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies?Eva Zebedin, Michael Freissmuth, Veronika Sexl
Pharmaceuticals (Basel, Switzerland)|December 1, 2020
CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer TreatmentLisa Scheiblecker, Karoline Kollmann, Veronika Sexl
Cell Death and Differentiation|May 13, 2017
It is a differentiation game: STAT5 in a new roleBarbara Maurer, Matthias Farlik, Veronika Sexl
Pageof 19